EGFR and non-small cell lung carcinoma: In phase III ADJUVANT/CTONG1104 study (NCT01405079), gefitinib increased the DFS (28.7 months vs. 18.0 months, HR=0.60, 95% CI: 0.42-0.87, p=0.0054) compared with the chemotherapy group (vinorelbine plus cisplatin) in completely resected stage II-IIIA (N1-N2) EGFR mutation-positive NSCLC (37).